Evidence map›Paper›PMID 35384272›Full record

Observational studyAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons2022

Neutralizing antibody response against the B.1.617.2 (delta) and the B.1.1.529 (omicron) variants after a third mRNA SARS-CoV-2 vaccine dose in kidney transplant recipients.

Louise Benning, Christian Morath, Marie Bartenschlager, Heeyoung Kim, Marvin Reineke, Jörg Beimler, Mirabel Buylaert, Christian Nusshag, Florian Kälble, Paula Reichel and 15 more

Open access · bronzeAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Observational
  15. Observational
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 4 institutions in 2 countries.

Louise BenningDepartment of Nephrology, University of Heidelberg, Heidelberg, Germany.ORCID 0000-0002-8366-2100
Christian MorathDepartment of Nephrology, University of Heidelberg, Heidelberg, Germany.ORCID 0000-0003-2218-7817
Marie BartenschlagerDepartment of Infectious Diseases, Molecular Virology, University of Heidelberg, Heidelberg, Germany.
Heeyoung KimDepartment of Infectious Diseases, Molecular Virology, University of Heidelberg, Heidelberg, Germany.
Marvin ReinekeDepartment of Nephrology, University of Heidelberg, Heidelberg, Germany.
Jörg BeimlerDepartment of Nephrology, University of Heidelberg, Heidelberg, Germany.
Mirabel BuylaertDepartment of Nephrology, University of Heidelberg, Heidelberg, Germany.
Christian NusshagDepartment of Nephrology, University of Heidelberg, Heidelberg, Germany.ORCID 0000-0001-7776-3784
Florian KälbleDepartment of Nephrology, University of Heidelberg, Heidelberg, Germany.
Paula ReichelDepartment of Nephrology, University of Heidelberg, Heidelberg, Germany.
Maximilian TöllnerDepartment of Nephrology, University of Heidelberg, Heidelberg, Germany.
Matthias SchaierDepartment of Nephrology, University of Heidelberg, Heidelberg, Germany.ORCID 0000-0003-1040-1150
Katrin KleinDepartment of Nephrology, University of Heidelberg, Heidelberg, Germany.
Vladimir BenesGenomics Core Facility, European Molecular Biology Laboratory, Heidelberg, Germany.
Tobias RauschGenomics Core Facility, European Molecular Biology Laboratory, Heidelberg, Germany.
Susanne RiegerDepartment of Pediatrics I, University Children's Hospital Heidelberg, Heidelberg, Germany.
Maximilian StichDepartment of Pediatrics I, University Children's Hospital Heidelberg, Heidelberg, Germany.
Burkhard TönshoffDepartment of Pediatrics I, University Children's Hospital Heidelberg, Heidelberg, Germany.ORCID 0000-0002-6598-6910
Niklas WeidnerDepartment of Virology, University of Heidelberg, Heidelberg, Germany.
Paul SchnitzlerDepartment of Virology, University of Heidelberg, Heidelberg, Germany.
Martin ZeierDepartment of Nephrology, University of Heidelberg, Heidelberg, Germany.
Caner SüsalInstitute of Immunology, University of Heidelberg, Heidelberg, Germany.
Thuong Hien TranInstitute of Immunology, University of Heidelberg, Heidelberg, Germany.
Ralf BartenschlagerDepartment of Infectious Diseases, Molecular Virology, University of Heidelberg, Heidelberg, Germany.
Claudius SpeerDepartment of Nephrology, University of Heidelberg, Heidelberg, Germany.ORCID 0000-0002-3668-5916
Heidelberg University · DEEuropean Molecular Biology Laboratory · DEGerman Cancer Research Center · DEKoç University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Seroconversion after COVID-19 vaccination is impaired in kidney transplant recipients. Emerging variants of concern such as the B.1.617.2 (delta) and the B.1.1.529 (omicron) variants pose an increasing threat to these patients. In this observational cohort study, we measured anti-S1 IgG, surrogate neutralizing, and anti-receptor-binding domain antibodies three weeks after a third mRNA vaccine dose in 49 kidney transplant recipients and compared results to 25 age-matched healthy controls. In addition, vaccine-induced neutralization of SARS-CoV-2 wild-type, the B.1.617.2 (delta), and the B.1.1.529 (omicron) variants was assessed using a live-virus assay. After a third vaccine dose, anti-S1 IgG, surrogate neutralizing, and anti-receptor-binding domain antibodies were significantly lower in kidney transplant recipients compared to healthy controls. Only 29/49 (59%) sera of kidney transplant recipients contained neutralizing antibodies against the SARS-CoV-2 wild-type or the B.1.617.2 (delta) variant and neutralization titers were significantly reduced compared to healthy controls (p < 0.001). Vaccine-induced cross-neutralization of the B.1.1.529 (omicron) variants was detectable in 15/35 (43%) kidney transplant recipients with seropositivity for anti-S1 IgG, surrogate neutralizing, and/or anti-RBD antibodies. Neutralization of the B.1.1.529 (omicron) variants was significantly reduced compared to neutralization of SARS-CoV-2 wild-type or the B.1.617.2 (delta) variant for both, kidney transplant recipients and healthy controls (p < .001 for all).

Indexed as

COVID-19Kidney TransplantationAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesHumansImmunoglobulin GmRNA VaccinesRNA, MessengerSARS-CoV-2Transplant RecipientsVaccines, SyntheticViral Envelope ProteinsAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesImmunoglobulin GmRNA VaccinesRNA, MessengerVaccines, SyntheticViral Envelope Proteinsclinical decision-makingclinical researchimmune modulationimmunosuppressionkidney transplantationnephrologypracticesolid organ transplantationvaccine

Identifiers

PMID35384272
PMCPMC9111366
OpenAlexW4223963084

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.